Y-Intercept (HK)’s Amylyx Pharmaceuticals AMLX Stock Holding History

Y-Intercept (HK)’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.15M	Buy	+39,373	New	+$1.04M	0.03%	941
2025 Q3	–	Sell	-240,379	Closed	-$1.54M	–	1542
2025 Q2	$1.54M	Buy	+240,379	New	+$1.17M	0.04%	725
2025 Q1	–	Sell	-14,809	Closed	-$56K	–	1167
2024 Q4	$56K	Buy	+14,809	New	+$69.7K	﹤0.01%	1117
2024 Q3	–	Sell	-118,105	Closed	-$224K	–	1275
2024 Q2	$224K	Sell	118,105 -223,412	-65%	-$433K	0.01%	1142
2024 Q1	$970K	Buy	341,517 +292,313	+594%	+$3.82M	0.07%	401
2023 Q4	$724K	Buy	+49,204	New	+$754K	0.07%	444

Other funds holding AMLX

Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Parsons Capital Management Providence, Rhode Island $2.29B AUM 21.99% 1-Year Est. Return

Y-Intercept (HK)'s AMLX Position: Q3 2026 in Review

Y-Intercept (HK) opened a new position in Amylyx Pharmaceuticals (AMLX) in Q3 2026: 39,373 shares worth $1.15M. The stake represents 0.03% of the portfolio and ranks #941 among its holdings. This is a return to the name: Y-Intercept (HK) previously reported a position in AMLX as recently as Q2 2025.

Y-Intercept (HK) first reported a position in AMLX in Q4 2023 and has held it in 6 quarters since. The position peaked at $1.54M in Q2 2025. 50 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

Y-Intercept (HK) held 39,373 shares of Amylyx Pharmaceuticals worth $1.15M as of Q3 2026.
Amylyx Pharmaceuticals was a new Y-Intercept (HK) position in Q3 2026.
Amylyx Pharmaceuticals made up 0.03% of Y-Intercept (HK)'s portfolio in Q3 2026, its #941 holding.
Y-Intercept (HK) first reported a position in Amylyx Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
Y-Intercept (HK)'s Amylyx Pharmaceuticals position peaked at $1.54M in Q2 2025.
50 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.